About Integer Holdings Corporation Common Stock (ITGR)
Integer Holdings Corp is a leading provider of advanced medical devices and components, specializing in the design and manufacture of innovative solutions for the healthcare industry. The company focuses on developing products that support critical therapeutic and diagnostic applications, catering to a diverse range of medical markets including cardiovascular, orthopedics, and neuromodulation. Integer's expertise encompasses a variety of technologies, enabling it to deliver high-quality, reliable medical products that enhance patient outcomes and drive advancements in healthcare. Through strategic partnerships and a commitment to innovation, Integer Holdings Corp plays a vital role in improving lives and expanding the possibilities of medical technology. Read More
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Integer Holdings Corporation (NYSE: ITGR) securities between July 25, 2024 and October 22, 2025. Integer is a leading global medical device contract manufacturer specializing in cardiac rhythm management and cardiovascular products.
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until February 9, 2026 to file lead plaintiff applications in a securities class action lawsuit against Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR), if they purchased or otherwise acquired the Company’s shares between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Integer Holdings Corporation (NYSE: ITGR) common stock between July 25, 2024 and October 22, 2025, both dates inclusive (the “Class Period”). Integer is a medical device contract manufacturer.
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) investors concerning the Company’s possible violations of the federal securities laws.
Integer Holdings Corp (ITGR) is a value stock with strong valuation metrics, solid profitability, and a stable financial position, indicating potential market undervaluation.
Looking back on medical devices & supplies - specialty stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Integer Holdings (NYSE:ITGR) and its peers.
Integer Holdings’ third quarter results were overshadowed by management’s acknowledgment of unexpected headwinds tied to lower-than-anticipated adoption of several new products. CEO-elect Payman Khales explained that multiple customers revised their forecasts downward, impacting both the Cardio & Vascular and Neuromodulation product lines. These customer-driven changes, which management described as “highly unusual,” led to a reduction in the company’s full-year outlook. Khales clarified, “We recently received customer updates related to the adoption of new products in the market that we expect will impact the next 3 quarters.”
Medical technology company Integer Holdings (NYSE:ITGR) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.4% year on year to $467.7 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $1.79 per share was 6.8% above analysts’ consensus estimates.
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares plummeting a staggering 31.4%. The significant sell-off came despite the company reporting strong third-quarter 2025 earnings that largely met or exceeded
Shares of medical technology company Integer Holdings (NYSE:ITGR)
fell 31.4% in the afternoon session after the company reported third quarter earnings which revealed a significant reduction in its full-year profit forecast.
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Medical technology company Integer Holdings (NYSE:ITGR) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.4% year on year to $467.7 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $1.79 per share was 6.8% above analysts’ consensus estimates.
